Monneret G, Seffert O, Debard A L, Gutowski M C, Couprie N, Larbre J P, Tebib J, Bienvenu J
Laboratoire d'immunologie, Centre hospitalier Lyon-Sud.
Ann Biol Clin (Paris). 2000 Jul-Aug;58(4):461-6.
One of the strongest known association between human leukocyte antigen (HLA) phenotype and disease is that of ankylosing spondylitis and HLA-B27. Thus, the determination of HLA-B27 status is an useful tool in the diagnosis of ankylosing spondylitis. To date, the 2 reference methods for HLA typing (microlymphocytotoxicity and molecular biology techniques), are costly in terms of both technician time and materials, and require a great deal of experience. In total, these techniques are not well-suited for routine application in clinical immunology laboratories. Use of flow cytometry has recently been applied for HLA-B27 typing. Nevertheless, it requires an extensive validation protocol. We developed a flow cytometry technique as standardized as possible (whole blood, automated lysing system, automated photomultiplier voltage calibration, definition of thresholds stable with time) and validated our results by comparison with microlymphocytotoxicity. In total, 326 samples were analyzed. We found 99% of concordant results between the 2 techniques, and neither false positive results nor false negative results with flow cytometry could be observed. These results illustrate the reliability of the protocol. It should be remembered that reference technique remains necessary to confirm the few results (< 1%) found in "grey zone" by flow cytometry. Standardization of flow cytometry techniques, as described in this work for HLA B27, seems to be a reasonable goal for the next decade in clinical immunology laboratories.
人类白细胞抗原(HLA)表型与疾病之间已知的最强关联之一是强直性脊柱炎与HLA - B27之间的关联。因此,确定HLA - B27状态是诊断强直性脊柱炎的一项有用工具。迄今为止,HLA分型的两种参考方法(微量淋巴细胞毒性和分子生物学技术)在技术人员时间和材料方面成本都很高,并且需要大量经验。总体而言,这些技术不太适合在临床免疫学实验室中常规应用。流式细胞术最近已用于HLA - B27分型。然而,它需要广泛的验证方案。我们开发了一种尽可能标准化的流式细胞术技术(全血、自动裂解系统、自动光电倍增管电压校准、随时间稳定的阈值定义),并通过与微量淋巴细胞毒性比较来验证我们的结果。总共分析了326个样本。我们发现这两种技术之间有99%的结果一致,并且未观察到流式细胞术的假阳性结果或假阴性结果。这些结果说明了该方案的可靠性。应该记住,参考技术对于确认流式细胞术在“灰色区域”发现的少数结果(<1%)仍然是必要的。如本研究中针对HLA B27所述,流式细胞术技术的标准化似乎是临床免疫学实验室未来十年的一个合理目标。